Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The conversation discusses using GHK-Cu for hair loss, with one user suggesting subcutaneous administration for better control. The effectiveness of topical application is questioned due to a lack of reliable reviews.

Longitudinal partial follicular unit transplantation involves extracting part of the donor follicular unit, allowing the donor area to maintain hair production and potentially increasing transplant yield. The conversation questions if this method is practiced in clinics or remains theoretical, and whether it relates to hair cloning or multiplication.

The conversation discusses concerns about starting topical finasteride due to high estradiol levels and the potential risk of gynecomastia. Suggestions include using ultrasensitive estradiol tests and considering aromatase inhibitors like zinc, ZMA, or DIM supplements.

The conversation discusses alternatives to 5AR inhibitors for hair loss treatment, suggesting options like minoxidil, KX-826, pyrilutimide, microneedling, and topical bicalutamide. Concerns about side effects and the effectiveness of these treatments are also highlighted.

Amplifica has not provided updates on SCUBE3 and AMP-303, raising concerns about their trial outcomes. Users also mention other treatments like Minoxidil, finasteride, RU58841, PP405, and ET-03.

The user is experiencing irritation from using PG with RU58841 and is seeking alternative solutions like K&B in the UK. They report redness, itchiness, and flaky skin from the current treatment.

The conversation discusses potential future hair loss treatments, including SCUBE3, hair follicle cloning, and GT20029, with mentions of past disappointments like CosmeRNA and hopes for treatments like Verteporfin for infinite donor hair.

The conversation discusses using very low dose topical finasteride to achieve specific serum DHT reduction percentages. It concludes that finasteride dosage increases linearly between 5-30% DHT reduction but requires exponential increases for reductions up to 70%.

Amplifica's AMP-303 showed a modest increase in hair growth, but results were inconsistent and potentially misleading. Hyaluronic acid and osteopontin are being explored for hair growth, with varying effects on different hair types and conditions.

Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.

PP405 was ineffective for hair growth as some follicles were already active before treatment, raising doubts about its efficacy. Users discussed other hair loss treatments like Minoxidil, finasteride, and RU58841, expressing skepticism and hope for future solutions.

Oral Dutasteride and topical Finasteride may have similar effects on scalp DHT, but topical Dutasteride might be less effective due to poor absorption. Combining oral Dutasteride with topical Finasteride could potentially enhance results by blocking DHT in both the scalp and serum.

The user shared 8 months of hair loss progress using dutasteride, oral minoxidil, RU58841 mixed with liquid minoxidil, and foam minoxidil. They started all treatments simultaneously, using RU58841 for its different mechanism of action.

Younger generations now view receding hairlines as baldness, increasing the use of treatments like minoxidil and finasteride. Social media and changing beauty standards have intensified focus on hairlines, altering perceptions of baldness.

The user shared progress on hair regrowth after a third verteporfin procedure, using oral dutasteride, extended-release oral minoxidil, and occasional microneedling. The results were positively received by others.

A 30-year-old male switched from finasteride to a combination of dutasteride, oral minoxidil, and RU58841, achieving significant hair growth without side effects. He plans to add GHK-Cu peptide to his regimen for further improvement.

The conversation discusses hair loss treatments, specifically Regenera stem cells and exosomes from 'Cellgenic' umbilical cord donors. The user has been using topical minoxidil 5% and 0.001% estradiol for a year without seeing effects, and another user mentions the importance of microneedling.

The user experienced hairline improvement using topical 5% Minoxidil in the first month and 8% Minoxidil with 0.3% topical finasteride in the second month, along with batana oil, Vitamin D, and biotin. The user takes two doses daily and reports a thicker, stronger hairline.

The user shared progress pictures after 8 months of using oral finasteride and topical minoxidil for hair loss, noting a plateau and considering adding dutasteride and oral minoxidil. They experienced a shedding phase but saw some regrowth, and also use a derma stamp and GHK-CU injections.

The user experienced significant hair regrowth and fullness after starting hormone replacement therapy (HRT) with sublingual estrogen and spironolactone, in addition to using a topical solution of minoxidil, finasteride, ketoconazole, and biotin. They noted initial shedding phases but emphasized that shedding is a sign of future growth.

The conversation is about a user's progress in treating diffuse hair thinning using a topical regimen including finasteride, minoxidil, ketoconazole, microneedling, saw palmetto, collagen, and vitamins, along with lifestyle changes. The user plans to switch from topical to oral finasteride for potentially better results.

Reducing scalp DHT doesn't directly correlate with preventing hair miniaturization, as different follicles have varying sensitivity levels. Dutasteride at 0.5 mg and 2.5 mg shows minimal visual difference in hair regrowth, with side effects being a consideration for higher doses.

Switching from oral to topical dutasteride can cause shedding due to changes in DHT levels, and it's recommended to overlap both treatments to minimize this effect. Topical dutasteride may cause scalp irritation, and the user is considering dutasteride mesotherapy as an alternative.

Minoxidil use led to excessive eyebrow and forehead hair growth, prompting grooming advice like waxing, tweezing, and shaving. Some suggested reducing dosage or considering electrolysis for permanent hair removal.

The post discusses whether a topical serum with 0.3% finasteride, 6% minoxidil, and essential oils is as effective as a spray with the same concentrations but different ingredients for scalp absorption. The user is seeking advice on which formulation absorbs better into the scalp.

The user saw significant hair regrowth using topical minoxidil and finasteride, even on areas not directly treated. They used local Algerian products with 5% minoxidil and 0.1% finasteride and reported no side effects.

A person transitioning is using 2mg sublingual estradiol and 2.5mg oral minoxidil daily for hair regrowth, noting significant progress in three months. They plan to increase estrogen dosage and consider adding dutasteride, discussing the effects and challenges of transitioning.

A 19-year-old used a 0.01% topical finasteride formula, which unexpectedly lowered DHT levels significantly. They are considering reducing the dose further and exploring alternatives like ketoconazole shampoo, KX826, and CB to manage hair loss while minimizing systemic absorption.

The conversation discusses applying KX826 for hair loss without wasting it, with a suggestion to buzz the hair for easier application. The user considers using a 0.9% version after finding the 0.5% version insufficient.

A humorous discussion about random, long hairs appearing on the body, with no connection to hair loss treatments like Minoxidil, finasteride, or RU58841. Participants share personal anecdotes about these unusual hairs.